Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
238 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2014', provides an overview of the Congestive Heart Failure (Heart Failure)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Congestive Heart Failure (Heart Failure) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Congestive Heart Failure (Heart Failure) Overview 9 Therapeutics Development 10 Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview 10 Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis 11 Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies 12 Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes 17 Congestive Heart Failure (Heart Failure) - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Congestive Heart Failure (Heart Failure) - Products under Development by Companies 22 Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes 26 Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 28 Acorda Therapeutics, Inc. 28 ARCA biopharma, Inc. 29 Asklepios BioPharmaceutical, Inc. 30 Athersys, Inc. 31 Bayer AG 32 BEAT BioTherapeutics Corp. 33 Bioheart, Inc. 34 BioLineRx, Ltd. 35 Bristol-Myers Squibb Company 36 Cardio3 BioSciences SA 37 Cardioxyl Pharmaceuticals, Inc. 38 Celladon Corporation 39 Cellmid Limited 40 GlaxoSmithKline plc 41 Glucox Biotech AB 42 Innopharmax Inc. 43 IntelliCell BioSciences Inc. 44 Johnson & Johnson 45 Juventas Therapeutics, Inc. 46 La Jolla Pharmaceutical Company 47 Lead Pharma Holding B.V. 48 Les Laboratoires Servier SAS 49 Lonestar Heart, Inc. 50 Mast Therapeutics, Inc. 51 Merck & Co., Inc. 52 Mesoblast Limited 53 Mezzion Pharma Co. Ltd. 54 MI.TO. Technology S.r.L. 55 NeoStem, Inc. 56 Palatin Technologies, Inc. 57 PharmaIN Corporation 58 QUANTUM GENOMICS Corp. 59 Recardio GmbH 60 RedHill Biopharma Ltd. 61 RegenoCELL Therapeutics, Inc. 62 Target Heart Biotec Srl 63 Torrent Pharmaceuticals Limited 64 uniQure NV 65 Vicore Pharma AB 66 Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Combination Products 68 Assessment by Target 69 Assessment by Mechanism of Action 72 Assessment by Route of Administration 74 Assessment by Molecule Type 76 Drug Profiles 78 AdipoCell - Drug Profile 78 AdipoCell + MyoCell - Drug Profile 80 aladorian - Drug Profile 81 AMR-001 - Drug Profile 83 AntimiR-199a - Drug Profile 85 ARX-720 - Drug Profile 86 Autologous Vascular Cells Therapy - Drug Profile 87 BAY-1142524 - Drug Profile 88 BAY-868050 - Drug Profile 89 BBR-12 - Drug Profile 90 BNP-CHF - Drug Profile 91 bucindolol hydrochloride - Drug Profile 92 C-21 - Drug Profile 94 C3BSCQR-1 - Drug Profile 96 Calpain Inhibitor - Drug Profile 98 CARD-024 - Drug Profile 99 carvedilol CR - Drug Profile 101 carvedilol CR - Drug Profile 102 CEP-41750 - Drug Profile 103 CGEN-856 - Drug Profile 105 cimaglermin alfa - Drug Profile 107 CM-1 - Drug Profile 109 CMK-103 - Drug Profile 111 CTX-101 - Drug Profile 112 CTX-201 - Drug Profile 113 CXL-1036 - Drug Profile 114 Drug for Heart Failure - Drug Profile 115 Drug for Heart Failure-2 - Drug Profile 116 Drugs for Heart Failure-1 - Drug Profile 117 Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile 118 Gene Therapy for Congestive Heart Failure - Drug Profile 119 Gene Therapy for Ischemic Heart Failure - Drug Profile 120 Gene Therapy to Activate AC-6 for Congestive Heart Failure - Drug Profile 121 Gene Therapy to Activate S100-A1 for Congestive Heart Failure - Drug Profile 122 Gene Therapy to Activate S100-A1 for Heart Failure - Drug Profile 123 Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile 124 Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile 125 Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile 126 GSK-2798745 - Drug Profile 127 GSK-2881078 - Drug Profile 128 ITD-1 - Drug Profile 129 JNJ-54452840 - Drug Profile 130 JVS-100 - Drug Profile 132 LJPC-201 - Drug Profile 134 MicroRNAs for Heart Failure - Drug Profile 135 MK-7145 - Drug Profile 136 MP-3167 - Drug Profile 137 MTP-131 - Drug Profile 138 MultiStem - Drug Profile 140 Mydicar - Drug Profile 143 MyoCell - Drug Profile 145 PGC Based Natriuretic Peptides - Drug Profile 146 PL-3994 - Drug Profile 147 poloxamer - Drug Profile 149 Pyroglutaminated Serpinin - Drug Profile 151 QGC-101 - Drug Profile 152 REC-02 - Drug Profile 153 Recombinant Protein for Congestive Heart Failure - Drug Profile 154 RNAi Oligonucleotide to Inhibit STIM1 for Cardiovascular Disorders - Drug Profile 155 S-38844 - Drug Profile 156 serpinin - Drug Profile 157 Small Molecule to Inhibit BMP for Cardiovascular, CNS and Musculoskeletal Disorders - Drug Profile 158 Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile 159 Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 160 Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 161 Small Molecules to Agonize Beta 2 Adrenergic Receptor Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 162 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 163 Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 164 Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 165 Small Molecules to Inhibit PDE5 for Ischemia Reperfusion Injury - Drug Profile 166 Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile 167 SP-20202 - Drug Profile 168 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 169 Stem Cell Therapy for Heart failure - Drug Profile 170 Stem Cell Therapy for Heart Failure - Drug Profile 171 Stem Cell Therapy for Myocardial Infarction and Congestive Heart Failure - Drug Profile 172 TRC-4186 - Drug Profile 173 udenafil - Drug Profile 175 vepoloxamer - Drug Profile 177 XEN-105 - Drug Profile 178 Congestive Heart Failure (Heart Failure) - Recent Pipeline Updates 179 Congestive Heart Failure (Heart Failure) - Dormant Projects 217 Congestive Heart Failure (Heart Failure) - Discontinued Products 223 Congestive Heart Failure (Heart Failure) - Product Development Milestones 224 Featured News & Press Releases 224 Appendix 231 Methodology 231 Coverage 231 Secondary Research 231 Primary Research 231 Expert Panel Validation 231 Contact Us 232 Disclaimer 232
List of Tables Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2014 16 Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2014 17 Number of Products under Development by Companies, H2 2014 19 Number of Products under Development by Companies, H2 2014 (Contd..1) 20 Number of Products under Development by Companies, H2 2014 (Contd..2) 21 Number of Products under Development by Companies, H2 2014 (Contd..3) 22 Number of Products under Investigation by Universities/Institutes, H2 2014 24 Comparative Analysis by Late Stage Development, H2 2014 25 Comparative Analysis by Clinical Stage Development, H2 2014 26 Comparative Analysis by Early Stage Development, H2 2014 27 Products under Development by Companies, H2 2014 28 Products under Development by Companies, H2 2014 (Contd..1) 29 Products under Development by Companies, H2 2014 (Contd..2) 30 Products under Development by Companies, H2 2014 (Contd..3) 31 Products under Investigation by Universities/Institutes, H2 2014 32 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 33 Congestive Heart Failure (Heart Failure) - Pipeline by Acorda Therapeutics, Inc., H2 2014 34 Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H2 2014 35 Congestive Heart Failure (Heart Failure) - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2014 36 Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H2 2014 37 Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H2 2014 38 Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H2 2014 39 Congestive Heart Failure (Heart Failure) - Pipeline by Bioheart, Inc., H2 2014 40 Congestive Heart Failure (Heart Failure) - Pipeline by BioLineRx, Ltd., H2 2014 41 Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2014 42 Congestive Heart Failure (Heart Failure) - Pipeline by Cardio3 BioSciences SA, H2 2014 43 Congestive Heart Failure (Heart Failure) - Pipeline by Cardioxyl Pharmaceuticals, Inc., H2 2014 44 Congestive Heart Failure (Heart Failure) - Pipeline by Celladon Corporation, H2 2014 45 Congestive Heart Failure (Heart Failure) - Pipeline by Cellmid Limited, H2 2014 46 Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline plc, H2 2014 47 Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H2 2014 48 Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H2 2014 49 Congestive Heart Failure (Heart Failure) - Pipeline by IntelliCell BioSciences Inc., H2 2014 50 Congestive Heart Failure (Heart Failure) - Pipeline by Johnson & Johnson, H2 2014 51 Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H2 2014 52 Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2014 53 Congestive Heart Failure (Heart Failure) - Pipeline by Lead Pharma Holding B.V., H2 2014 54 Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H2 2014 55 Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H2 2014 56 Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H2 2014 57 Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H2 2014 58 Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H2 2014 59 Congestive Heart Failure (Heart Failure) - Pipeline by Mezzion Pharma Co. Ltd., H2 2014 60 Congestive Heart Failure (Heart Failure) - Pipeline by MI.TO. Technology S.r.L., H2 2014 61 Congestive Heart Failure (Heart Failure) - Pipeline by NeoStem, Inc., H2 2014 62 Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H2 2014 63 Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H2 2014 64 Congestive Heart Failure (Heart Failure) - Pipeline by QUANTUM GENOMICS Corp., H2 2014 65 Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H2 2014 66 Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H2 2014 67 Congestive Heart Failure (Heart Failure) - Pipeline by RegenoCELL Therapeutics, Inc., H2 2014 68 Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H2 2014 69 Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 70 Congestive Heart Failure (Heart Failure) - Pipeline by uniQure NV, H2 2014 71 Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H2 2014 72 Assessment by Monotherapy Products, H2 2014 73 Assessment by Combination Products, H2 2014 74 Number of Products by Stage and Target, H2 2014 76 Number of Products by Stage and Mechanism of Action, H2 2014 79 Number of Products by Stage and Route of Administration, H2 2014 81 Number of Products by Stage and Molecule Type, H2 2014 83 Congestive Heart Failure (Heart Failure) Therapeutics - Recent Pipeline Updates, H2 2014 185 Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2014 223 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H2 2014 224 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H2 2014 225 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H2 2014 226 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H2 2014 227 Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H2 2014 228 Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2014 229
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
